Tris

Tris Pharma Partners with Perigon Pharmacy 360 to Enhance Access to DYANAVEL® XR Tablets for the Treatment of Attention Deficit Hyperactivity Disorder

Retrieved on: 
Monday, October 30, 2023
Research, Mental Health, Neurology, FDA, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Ketan, Patient, Pharmacy, Ageing, Amphetamine, Theft, Physician, Pharma, Environment, Caregiver, Perigon, Partnership, XR, DSM-IV codes, Pain, Attention deficit hyperactivity disorder, Death, ADHD, Addiction, CII, Pharmaceutical industry, Tris

Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on attention deficit hyperactivity disorder (ADHD), pain, addiction and neurological disorders, today announced a new partnership with Perigon Pharmacy 360, a full-service, specialty digital pharmacy, to enhance accessibility, affordability and adherence for patients treating symptoms of ADHD with Tris’ DYANAVEL® XR (amphetamine) extended-release tablets.

Key Points: 
  • Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on attention deficit hyperactivity disorder (ADHD), pain, addiction and neurological disorders, today announced a new partnership with Perigon Pharmacy 360, a full-service, specialty digital pharmacy, to enhance accessibility, affordability and adherence for patients treating symptoms of ADHD with Tris’ DYANAVEL® XR (amphetamine) extended-release tablets.
  • The program is available across the United States, enabling nationwide access to DYANAVEL XR extended-release tablets.
  • Patients and physicians wishing to access the DYANAVEL Delivered program can learn more at www.dyanavel.com/delivered .
  • The DYANAVEL Delivered program is designed to help eliminate bottlenecks by delivering DYANAVEL XR extended-release tablets directly to patients and caregivers.

Tris Pharma Secures First ex-US Authorizations for Quillivant ER Oral Suspension and Quillivant ER Chewable Tablet for the Treatment of Attention Deficit Hyperactivity Disorder

Retrieved on: 
Monday, September 25, 2023
Other Health, Research, General Health, Pharmaceutical, Consumer, Mental Health, Parenting, Children, Science, Biotechnology, Neurology, Health, Ketan, Pharma, ER, Partnership, ADHD, Tablet, Methylphenidate, Pain, Attention deficit hyperactivity disorder, DSM-IV codes, Patient, Ageing, Health Canada, Dietary supplement, Pharmaceutical industry, Tris

Quillivant ER will be available as both an oral suspension and chewable tablet (known in the United States as Quillivant XR® and QuilliChew ER®, respectively).

Key Points: 
  • Quillivant ER will be available as both an oral suspension and chewable tablet (known in the United States as Quillivant XR® and QuilliChew ER®, respectively).
  • Quillivant ER is the first once-daily, long-acting, chewable and oral suspension formulations of methylphenidate to be approved for the treatment of ADHD in Canada.
  • Tris will manufacture Quillivant ER in the United States and export to KYE Pharmaceuticals for Canadian patients.
  • Quillivant ER has demonstrated onset of action as soon as 45 minutes through 12 hours post-dose, providing consistent, continuous delivery throughout the day.

Tris Pharma Presents Data Reinforcing Limited Abuse Potential of Investigational Pain Therapy Cebranopadol at the 2023 PAINWeek Conference

Retrieved on: 
Tuesday, September 5, 2023
Health, Neurology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Ketan, Pharma, Naloxone, Oxycodone, Food and Drug Administration, Opioid use disorder, ADHD, DSM-IV codes, OUD, VAS, FQ, Physical dependence, II, Pain, Visual analogue scale, NOP, Patient, Risk, MOP, Neuropathic pain, Pain management, Addiction, Drug, HAP, FDA, Tramadol, Food, Pharmaceutical industry, Tris

Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on ADHD, pain and neurological disorders, today announced new data from a human abuse potential (HAP) study of cebranopadol (TRN-228) which suggest the investigational compound has significantly lower abuse potential compared to both schedule II and schedule IV opioids.

Key Points: 
  • Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on ADHD, pain and neurological disorders, today announced new data from a human abuse potential (HAP) study of cebranopadol (TRN-228) which suggest the investigational compound has significantly lower abuse potential compared to both schedule II and schedule IV opioids.
  • The findings will be shared on Thursday, September 7, in a poster presentation at the 2023 PAINWeek conference in Las Vegas.
  • Study participants randomly received a single dose of placebo, cebranopadol 600 μg, cebranopadol 1000 μg, tramadol IR 600 mg or oxycodone IR 40 mg.
  • The difference between the good effects and bad effects of drugs have been linked to their abuse potential.

Tris Pharma Awarded Five-Year Grant of Up to $16.6M From the NIH's National Institute on Drug Abuse to Advance Cebranopadol for the Treatment of Opioid Use Disorder

Retrieved on: 
Monday, August 28, 2023
Research, Mental Health, Neurology, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Other Science, Ketan, Pharma, Wayne State University, Opioid, Public, Initiative, ADHD, DSM-IV codes, Opioid use disorder, OUD, FQ, Heroin, Bangladesh Technical Education Board, Pain, Cocaine, NOP, National Institute on Drug Abuse, MOP, NIDA, Pain management, Drug, Schedule 2, FDA, NIH, Disease, Pharmaceutical industry, Tris

Through the Helping to End Addiction Long-term® Initiative (NIH HEAL Initiative®), NIH has awarded grants to fund the optimization of new therapies to prevent and treat opioid use disorder (OUD).

Key Points: 
  • Through the Helping to End Addiction Long-term® Initiative (NIH HEAL Initiative®), NIH has awarded grants to fund the optimization of new therapies to prevent and treat opioid use disorder (OUD).
  • Cebranopadol is an investigational, dual nociception/orphanin FQ peptide (NOP) receptor and µ-opioid peptide (MOP) receptor agonist.
  • Further, cebranopadol has demonstrated reduced cocaine and heroin self-administration and drug-seeking behaviors, reinforcing its potential as an effective treatment for OUD.
  • The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Tris Pharma Expands Leadership Team as Company Broadens Commercial Portfolio and Progresses Clinical Pipeline

Retrieved on: 
Tuesday, May 2, 2023
Biotechnology, Mental Health, Other Health, Health, Pharmaceutical, Ketan, Pharma, Endocrinology, IPO, Drug development, University, Allergy, Liver disease, Baxter, Pennsylvania State University, Infection, DSM-IV codes, Multimedia, Research, FQ, Marketing, Pain, U.S. FDA, Anesthesia, Organization, Molecular biology, Villanova University, Business administration, NOP, Patient, MOP, Pain management, Nursing care plan, Cardiology, FDA, Therapy, Psychiatry, Pharmaceutical industry, Medical imaging, Science, Mallinckrodt, Tris, ADHD, Biochemistry, Biology

Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on ADHD, pain and neurological disorders, today announced the appointments of Thomas Englese as chief commercial officer and Marc Lesnick, Ph.D., as chief development officer.

Key Points: 
  • Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on ADHD, pain and neurological disorders, today announced the appointments of Thomas Englese as chief commercial officer and Marc Lesnick, Ph.D., as chief development officer.
  • View the full release here: https://www.businesswire.com/news/home/20230502005475/en/
    Marc Lesnick, Ph.D., has been appointed chief development officer for Tris Pharma, a commercial-stage biopharmaceutical company focused on ADHD, pain and neurological disorders.
  • Prior to joining Tris Pharma, he was the chief commercial officer at Aziyo Biologics, where he oversaw multiple business units, profitably negotiated commercial partnerships with distinguished organizations and was a key leader of the company’s successful IPO team.
  • “Tris Pharma has a robust and expanding portfolio of clinically proven, best-in-class ADHD therapies,” said Englese.

Tris Pharma and Pediatrix Therapeutics Announce Expansion of Partnership to Commercialize Tris's ADHD Portfolio and Pipeline Products in China

Retrieved on: 
Thursday, December 1, 2022
Ketan, Psychology, Allergy, Psychiatry, Attention, CMC, ADHD, Narcolepsy, Risk, Pain, Partnership, Therapy, Physician, Patient, Neurology, Arm, Attention deficit hyperactivity disorder, Neonatology, CNS, Cerebral palsy, Multiple sclerosis, Addiction, FDA, Spasticity, Pharmaceutical industry, Tris

Mr. Zhang Cheng, CEO Pediatrix Therapeutics, added that, "ADHD has serious impact on children's psychology, social functions and family relationships.

Key Points: 
  • Mr. Zhang Cheng, CEO Pediatrix Therapeutics, added that, "ADHD has serious impact on children's psychology, social functions and family relationships.
  • Pediatrix and Tris have reached a strategic collaboration for several novel ADHD products to address patients' unmet needs in China.
  • Pediatrix Therapeutics is a biopharmaceutical company focusing on developing and commercializing high quality, pediatric-friendly and affordable therapeutics and healthcare products to children and families in China.
  • Founded in 2021, Pediatrix Therapeutics has built a portfolio of more than 10 products in the therapeutics areas of interest, including psychiatry, neurology, neonatology, allergy and immunology.

ANGUS LAUNCHES COMMERCIAL PRODUCTION OF HEPES BUFFER

Retrieved on: 
Tuesday, October 25, 2022
ISO, HEPES, ISO 9001:2015, Biotechnology, Cell, Deoxyribonuclease, Immunoprecipitation, Company, ANGUS, Multi, CEO, Buffer, Tris, AMP, INCI, Ribonuclease, TRIS, List of life sciences, Fine chemical

BUFFALO GROVE, Ill., Oct. 25, 2022 /PRNewswire/ -- ANGUS Chemical Company ("ANGUS" or "Company"), a leading global manufacturer and marketer of specialty chemicals for Life Sciences and Industrial markets, today announced the commercial launch of HEPES buffer produced at its Sterlington, Louisiana facility.

Key Points: 
  • BUFFALO GROVE, Ill., Oct. 25, 2022 /PRNewswire/ -- ANGUS Chemical Company ("ANGUS" or "Company"), a leading global manufacturer and marketer of specialty chemicals for Life Sciences and Industrial markets, today announced the commercial launch of HEPES buffer produced at its Sterlington, Louisiana facility.
  • HEPES is multi-purpose biological buffer often used to maintain a physiological pH which provides the ideal environment for cells to grow and thrive.
  • HEPES buffer (INCI: Hydroxyethylpiperazine Ethane Sulfonic Acid) can also be used in combination with other ingredients to support the quality and performance of skincare and cosmetics products.
  • "The expansion into commercial production of HEPES is a natural fit with our strategy to become the world's most transparent and dependable manufacturer of essential upstream and downstream bioprocessing chemistries," said ANGUS President and CEO David Neuberger.

Tris Pharma Announces US District Court Upholds Validity of QuilliChew ER® Patents; Rules Teva Infringes Tris Patents

Retrieved on: 
Thursday, August 18, 2022
Ketan, Death, Breast milk, ADHD, MAOI, Depression, The, Raynaud syndrome, Lists of diseases, Syncope, PKU, CNS, Sudden death, Abbreviated New Drug Application, Growth, United States district court, Phenylalanine, District, Suicide, Numb, Pain, Theft, ANDA, Attention deficit hyperactivity disorder, Court, Patient, Narcolepsy, Stroke, Finger, Chest pain, Degenerative disease, Priapism, Methylphenidate, Central nervous system, Peripheral vasculopathy, Spasticity, Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc., Child, District court, Cerebral palsy, Heart rate, Blood pressure, Color, Tablet, Phenylketonuria, Boxed warning, Ventricular septal defect, CII, Allergy, Attention deficit hyperactivity disorder predominantly inattentive, Multiple sclerosis, Montana District Courts, Temperature, Teva, Generic drug, Pharmaceutical industry, Residential care, Birth control, Tris

The ruling prevents Teva from launching generic versions of QuilliChew ER until the expiration of Tris's patent portfolio providing exclusivity until August 2033.

Key Points: 
  • The ruling prevents Teva from launching generic versions of QuilliChew ER until the expiration of Tris's patent portfolio providing exclusivity until August 2033.
  • "The decision of the District Court not only confirms the validity and infringement of our QuilliChew ER patents, but also validates the innovative nature of our LiquiXRtechnology which we utilized to develop QuilliChew ER and our other branded ADHD medications."
  • QuilliChew ER is approved for treatment of ADHD in people 6 years and older.
  • Call the doctor right away if any signs of unexplained wounds appear on fingers or toes while taking QuilliChew ER.

Tris Pharma Announces Development of a Very Low Sodium and Once-Nightly Oxybate Formulation

Retrieved on: 
Wednesday, July 27, 2022
Ketan, Somnolence, Time, Absorption, Multiple sclerosis, Hess, EDS, Jazz Pharmaceuticals, Trial of the century, Narcolepsy, Classification, List of Hindawi academic journals, Hallucination, Incidence, GM, Kingsley v. Hendrickson, CNS, Spasticity, Knowledge Organization (journal), Excessive daytime sleepiness, Epidemiology, Cataplexy, Sleep, ADHD, Wakefulness, Patient, Sodium, Cerebral palsy, Pain, Emotion, Hypertension, Heart failure, Sleep paralysis, Sodium oxybate, Prevalence, Neurological disorder, Pharmaceutical industry, Tris

The Tris oxybate formulation is believed to provide an advantage over approved therapies by utilizing Tris's proprietary LiquiXR technology platform and our newly developed RaftWorks design to provide a unique oxybate formulation offering both once-nightly dosing, and very low sodium content.

Key Points: 
  • The Tris oxybate formulation is believed to provide an advantage over approved therapies by utilizing Tris's proprietary LiquiXR technology platform and our newly developed RaftWorks design to provide a unique oxybate formulation offering both once-nightly dosing, and very low sodium content.
  • The Tris oxybate formulation seeks to improve on existing therapies by providing convenient once per night dosing, and significantly reduced sodium content such that it will contain less than 100 mg of sodium per 9.0 gm of maximum sodium oxybate equivalent dose.
  • Based on the significant potential advantage the Tris oxybate formulation could provide over existing available therapies, Tris is pursuing an Orphan Drug Designation for its unique oxybate formulation.
  • The Tris oxybate product achieved its clinical objectives by combining two distinct proprietary Tris technologies: the LiquiXR platform, and the newly developed RaftWorks design.

Tris Pharma announces U.S. Court of Appeals for the Federal Circuit Affirms Validity of Quillivant XR® Patents; Rules Teva Infringes Tris Patents

Retrieved on: 
Wednesday, July 20, 2022
Ketan, XR, Multiple sclerosis, Chest pain, ANDA, Attention deficit hyperactivity disorder predominantly inattentive, Federal Circuit Court of Australia, Priapism, Research, The, Raynaud syndrome, Ventricular septal defect, Hydrogen chloride, List, Finger, CNS, Methylphenidate, Spasticity, Narcolepsy, Lists of diseases, Tris, Boxed warning, Degenerative disease, Numb, Suicide, ADHD, Abbreviated New Drug Application, Peripheral vasculopathy, Mania, CII, CAFC, Patient, Cerebral palsy, Psychosis, Pain, Color, Depression, United States Court of Appeals for the Federal Circuit, Attention deficit hyperactivity disorder, MAOI, District, Attention, Breast milk, United States district court, Actavis, Child, Generic drug, Risk management, Pharmaceutical industry, Medical device, Residential care, Birth control, Healthcare

"We are very pleased with the ruling of the CAFC, which affirms the strength of our patents protecting Quillivant XR.

Key Points: 
  • "We are very pleased with the ruling of the CAFC, which affirms the strength of our patents protecting Quillivant XR.
  • You and your doctor should decide if you will take Quillivant XR or breastfeed
    What should I avoid while taking Quillivant XR?
  • Quillivant XR should not be taken with MAOI medicines or if you stopped taking an MAOI in the last 14 days.
  • Quillivant XR may cause serious side effects, including:
    Other serious side effects include:
    Painful and prolonged erections (priapism) have occurred with methylphenidate.